Aim of the work: neoadjuvant chemotherapy in downstaging of each the primary tumour and axillary disease, reach pathological complete response to neo-adjuvant remedy have had a marked effect on loco-regional remedy concerns, boom opportunities facilitating surgical intervention compare its impact on surgical management of breast cancers either mastectomy or BCS.
Patients and Method: This retrospective study is carried out on one hundred female patients with documented breast cancer, examined in the medical oncology department & nuclear medicine remedy Sohag university hospitals and sohag cancers institute, at the period from (2013 - 2018).
Results: Number of patients identified before receiving neo-adjuvant chemotherapy asT2 become 15 instances (15%),32 cases (32%) become T3,24 cases(24%) was T4a, 24 instances (24%) T4b,3 instances (three%) changed into T4c and 2cases (2% ) became T4d.
The number of instances identified before receiving neo-adjuvant chemotherapy as N0 was4 cases (4%), N1 turned into 37 instances (37%), N2 became fifty-two instances (fifty-two %) and N3 turned into (7%).
Number of cases that identified postoperative T0 was 10 cases(10%),T1 turned into 10 instances(10%),T2 was 47 instances(forty seven%),T3 was21 cases (21%),T4a turned into 5cases (5%) and T4b turned into 7 instances (7%).
Some instances that turned into postoperative N0 turned into 11cases(eleven%), N1 turned into 57cases (fifty-seven %), N2 was29 cases (29%) and N3 turned into 3cases (3%).
Conclusion: Neo-adjuvant chemotherapy plays a vital role in downstaging of breast and axillary disease, facilitates surgical resection, takes part in pathological entire response and testing response to chemotherapy.